Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma

Daniel Dubinski1*, Sae-Yeon Won1, Maximilian Rauch2, Bedjan Behmanesh1, Lionel D. C. Ngassam1, Peter Baumgarten1, Christian Senft1, Patrick N. Harter3, Joshua D. Bernstock4, Thomas M. Freiman1, Volker Seifert1 and Florian Gessler1

1 Department of Neurosurgery, Goethe University Hospital, Frankfurt, Germany, 2 Institute of Neuroradiology, Goethe University, Frankfurt, Germany, 3 Neurological Institute (Edinger Institute), Goethe University, Frankfurt, Germany, 4 Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States

Purpose: The extent of preoperative peritumoral edema in glioblastoma (GBM) has been negatively correlated with patient outcome. As several ongoing studies are investigating T-cell based immunotherapy in GBM, we conducted this study to assess whether peritumoral edema with potentially increased intracranial pressure, disrupted tissue homeostasis and reduced local blood flow has influence on immune infiltration and affects survival.

Methods: A volumetric analysis of preoperative imaging (gadolinium enhanced T1 weighted MRI sequences for tumor size and T2 weighted sequences for extent of edema (including the infiltrative zone, gliosis etc.) was conducted in 144 patients using the Brainlab® software. Immunohistochemical staining was analyzed for lymphocytic- (CD 3+) and myelocytic (CD15+) tumor infiltration. A retrospective analysis of patient-, surgical-, and molecular characteristics was performed using medical records.

Results: The edema to tumor ratio was neither associated with progression-free nor overall survival (p=0.90, p=0.74). However, GBM patients displaying IDH-1 wildtype had a significantly higher edema to tumor ratio than patients displaying an IDH-1 mutation (p=0.01). Immunohistopathological analysis did not show significant differences in lymphocytic or myelocytic tumor infiltration (p=0.78, p=0.74) between these groups.

Conclusion: In our cohort, edema to tumor ratio had no significant correlation with immune infiltration and outcome. However, patients with an IDH-1 wildtype GBM had a significantly higher edema to tumor ratio compared to their IDH-1 mutated peer group. Further studies are necessary to elucidate the underlying mechanisms.

Keywords: immune infiltration, glioma microenvironment, dexamethasone, peritumoral edema, peritumoral edema zone

OPEN ACCESS

Edited by:
Lukas Bunse, German Cancer Research Center (DKFZ), Germany

Reviewed by:
Susanna Mandruzzato, University Hospital of Padua, Italy
Michael O. Breckwoldt, German Cancer Research Center (DKFZ), Germany

*Correspondence:
Daniel Dubinski
danieldubinski@gmail.com

Specialty section:
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

Received: 09 November 2020
Accepted: 09 March 2021
Published: 25 March 2021

Citation:
Dubinski D, Won S-Y, Rauch M, Behmanesh B, Ngassam LDC, Baumgarten P, Senft C, Harter PN, Bernstock JD, Freiman TM, Seifert V and Gessler F (2021) Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma. Front. Immunol. 12:627650. doi: 10.3389/fimmu.2021.627650
INTRODUCTION

Glioblastoma (GBM) patients frequently present with peritumoral edema as diagnosed with preoperative imaging, such as T2 or FLAIR MRI scan. Peritumoral edema in turn often causes severe neurological impairment and remains a challenging factor throughout treatment (1). The peritumoral edema in GBM is considered to be vasogenic and caused by increased vascular permeability as hypoxia induced capillary formations lack functional tight junctions, contain fenestration and irregular basal membrane endothelia (2). The disrupted blood brain barrier (BBB) leads to the extravasation of plasma into the brain parenchyma surrounding the lesion.

Furthermore, the hypoxic core of the GBM, often containing necrosis, results in VEGF secretion which in turn is a crucial mediator of peritumoral edema and disrupted tissue hemostasis. Although several studies have identified the synthetic corticosteroid dexamethasone (DEX) as unbeneﬁcial in terms of survival for edema treatment in GBM, it is still routinely used in clinics for peritumoral edema treatment in GBM (3, 4).

Peritumoral edema has been described as a strong propagator of malignant cell inﬁltration and several studies have confirmed the negative prognostic impact of high edema to tumor ratios in GBM, although the mechanisms remain unclear (5, 6). Perfusion-weighted imaging has been used to demonstrate 50% reduced regional cerebral blood- volume and ﬂow in peritumoral edema compared to the contralateral white matter (7). We therefore postulated that increased edema (including the inﬁltrative zone, gliosis etc.) to tumor ratio would inﬂuence the lymphocytic and myelocytic tumor inﬁltration in patients with GBM and could therefore be associated with a poor prognosis.

MATERIAL AND METHODS

Patients and Data Collection

For this retrospective analysis an ethical approval was obtained from the ethics committee of the University Hospital Frankfurt, Germany, (Identiﬁcation number: 20-676). As a non-interventional single-center study no patient consent was necessary.

Cohort

In total, 162 GBM patients that were treated at the authors’ institution between September 2008 and January 2013 were retrospectively analyzed. The inclusion criteria were tumor resection (stereotactic biopsies were excluded) with the histological conﬁrmation of WHO IV GBM without previous treatment such as radio- chemotherapy for low grade astrocytoma. Further inclusion criteria were the availability of a preoperative cranial MRI with gadolinium enhanced T1 sequences and T2 sequences.

Patient medical charts were analyzed by two neurosurgeons (D.D. and S.-Y.W.) and blinded to the preoperative radiological data. Tumor and edema volume were analyzed by an experienced neuroradiologist (M.R.) and two neurosurgeons (P.B. and B.B.) who were blinded to the medical chart data. Patient characteristics that were extracted from the medical chart including the preoperative Karnofsky performance scale (KPS), date of surgery, date of death or date of last contact, date of tumor progression that was deﬁned as the date of cranial MRI with progressive disease according to the RANO (8) criteria and/or the determination of the local interdisciplinary neurooncological tumor board.

Magnetic Resonance Imaging

Preoperative MRI scans were performed in the department of neuroradiology, Goethe University Hospital Frankfurt at a 3 Tesla Siemens Verio scanner. Gd-D03A-butilol (Gadovist®, Bayer Vital GmbH) was administered intravenously (0.2 ml/kg, 0.5-1 ml/sec) and imaging started 9 seconds after administration of the contrast agent.

Image Analysis

Image analysis was performed by a neuroradiologist (M.R.) and two neurosurgeons (P.B. and B.B.) that were blinded to patients’ molecular characteristics. Pre- and postoperative tumor and edema volumes were analyzed by semi-automatic segmentation with IPlanNet 3 (Cranial planning software, Brainlab AG, Feldkirchen, Germany). A representative analysis is displayed in Figure 1. All tumor segmentations were done semi-automatically with the ‘Smartbrush’ tool of the Brainlab Elements software. A two-dimensional segmentation was drawn in the axial image and a second two-dimensional segmentation was drawn in a coronal slide. These two segmentations automatically generated a three-dimensional graphic of the tumor. The three-dimensional graphic was then manually corrected by adding or erasing certain areas. A total of 144 segmentations were performed in this manner. Tumor volume was delineated on contrast enhanced T1-weighted images and necrotic areas were spared. Edema volume was measured on a non-enhancing T2-hyperintense image set in the same procedure. The extent of resection was calculated by the pre- and postoperative tumor volume. Gross total resection (GTR) was deﬁned as complete removal (100%) of contrast-enhancing tissue.

Tissue Specimen and Processing

For this analysis the formalin-fixed and parafﬁn-embedded (FFPE) tissue samples from 26 patients of a recently published cohort were used (4). Parafﬁn full mounts were processed as follows: 1. cutting into 3µm thick slices using a microtome (Leica Microsystems, Nussloch GmbH, Nussloch, Germany), 2. placing on microscope slides (SuperFrost, Thermo Scientiﬁc, Dreieich, Germany), 3. heating to 40°C for 20min and 4. storage in an incubator overnight (37°C). For staining, standardized protocols for the automated IHC slide staining system BOND-III (Leica Biosystems, Nussloch GmbH, Nussloch, Germany) were used including the following antibodies: CD3 (A0452; 1:500; Dako), CD15 (M3631; 1:2000; Dako). After hematoxylin-counterstaining slides were mounted, lymphocytic (myelocytic) inﬁltration was assessed by counting CD3 (CD15) positive stained cells, in a deﬁned tumor bearing area, using a Zeiss microscope (Axiophot, Carl Zeiss Microscopy GmbH, Jena,
Germany) with a Stereo Investigator (Version 4.34 software from MicroBrightField Inc.), subsequently obtaining the ratio of positive stained cells per mm² (9). A representative analysis is displayed in Figure 2.

**Statistics**

Data analysis was performed with IBM SPSS Statistics Version 23.0 (SPSS Inc., IBM Corp., Armonk, NY, USA). For patients and tumor characteristics, descriptive statistics were used. Fisher’s exact test was used for the comparison of categorical variables between the cohorts. For continuous parameters, the Wilcoxon-Mann-Whitney test was used. To test the impact of the variables, odds ratio (OR) with 95% confidence intervals (CI) were calculated. Results with p ≤ 0.05 were considered statistically relevant. To estimate the survival rates, the Kaplan-Meier analysis was used. The differences between curves were assessed using the log-rank test. Progression free survival (PFS) was defined as the time from diagnosis to first recurrence or death. Overall survival (OS) was defined as the time of first presentation to death.

**RESULTS**

**Patient Characteristics**

A total of 144 patients with primary GBM were treated at the authors’ institution between September 2008 and January 2013. Of those, 18 patients were excluded due to a lack of radiological data, loss to follow-up, and/or lack of molecular data. Of the analyzed cohort, 64 patients (44%) were female and 80 patients (56%) were male. Of all patients, 64 patients (44%) were under 60 years of age. In total, 63 patients had a Karnofsky performance scale (KPS) of less than 80 (44%). Preoperative dexamethasone treatment was observed in 57 patients (39%). Gross total resection (GTR) was achieved in 89 patients (62%). (6)-methylguanine-DNA methyltransferase (MGMT) promotor methylation was detected in 68 patients (47%) and an isocitrate dehydrogenase (IDH) (IDH1R132H-mutation) mutation was observed in 19 patients (13%). The median tumor volume on T1 + contrast preoperative MRI was 29.75 cm³ (IQR: 36.6) and median edema volume on T2 was 114 cm³ (IQR: 120.8). Median progression free survival (PFS) was 9 months (IQR: 11.5) and overall survival was 17 months (IQR: 19.5). Of the 144 patients with complete diagnostic histopathological analysis, 26 FFPE’s were available for further immunohistochemical analysis. Of those, median tumor infiltration (CD3+) were 0.18/mm² (IQR: 0.15) for lymphocytic (CD3+) cells and 0.08/mm² (IQR: 0.66) for myelocytic (CD15+) cells (see Table 1).

**Association of Edema to Tumor Ratio With Patient Characteristics**

According to the median preoperative MRI edema to tumor volume, patients were stratified into the high or low edema to tumor ratio groups. Patients of the high edema to tumor ratio group had 57% (n=41) female patients compared to 54% (n=39) in the low edema to tumor cohort. No significant differences regarding sex were observed between both groups (p=0.86; 95%CI: 0.57-2.16; OR 1.1). In the high edema to tumor cohort, 35 (49%) patients were under the age of 60 compared to 29 (40%) patients in the low edema to tumor cohort. No significant differences regarding age were observed between both groups. Moreover, 31 (43%) patients with a high edema to tumor ratio and 32 patients (44%) with a low edema to tumor ratio presented with a median preoperative Karnofsky performance scale (KPS) of less than 80. The preoperative KPS was not associated with edema to tumor ratio (p=0.99; 95%CI:0.48-1.82; OR: 0.9); see Table 2.

**Preoperative Dexamethasone Administration and Edema to Tumor Ratio**

Patient medical charts showed preoperative dexamethasone (DEX) administration present in 26 patients (36%) in the high edema to tumor ratio cohort vs. 31 patients (43%) in the low edema to tumor ratio cohort. Preoperative presence of DEX was not associated with a high edema to tumor ratio (p=0.49; 95%CI: 0.38-1.47; OR: 0.7; Table 2).
Association of Edema to Tumor Ratio With Operative Results
Gross total resection (GTR) was achieved in 45 patients (62%) in the high edema to tumor cohort and 44 patients (61%) in the low edema to tumor cohort. The operative result was independent of preoperative edema to tumor ratio (p=0.99; 95% CI: 0.54-2.07; OR: 1.0; Table 2).

Association of Edema to Tumor Ratio With Molecular Characteristics
In patients with a high edema to tumor ratio, the MGMT promotor was methylated (+) in 38 patients (53%) and in 30 patients (42%) of the low edema to tumor ratio cohort (p=0.40; 95% CI: 0.36-1.37; OR: 0.7). The MGMT promotor status was not significantly correlated with edema to tumor ratio. Isocitrate dehydrogenase 1 wildtype (IDH-1 wt) was observed in 68 patients (94%) with a high edema to tumor ratio and in 57 patients (79%) with a low edema to tumor ratio (p=0.01; 95% CI: 0.07-0.71, OR: 4.6 in multivariate analysis. (Table 2).

Survival Analysis Depending on Edema to Tumor Volume
Volumetric analysis displayed a median tumor size of 29.75cm³ (IQR: 37.52). Patients with a tumor smaller than 29.75cm³ were defined as low tumor volume and patients with tumor size larger than 29.75cm³ as high tumor volume. Patients with low tumor volume had a median OS of 17 months (IQR: 19) and a PFS of 9

TABLE 1 | Patient characteristics.

|                   | n=144 | Number(%)|
|-------------------|-------|-----------|
| Gender            |       |           |
| Male              | 80    | (56)      |
| Female            | 64    | (44)      |
| Age (years)       |       |           |
| <80               | 64    | (44)      |
| ≥80               | 80    | (56)      |
| Karnofsky performance scale |       |           |
| <80               | 63    | (44)      |
| ≥80               | 81    | (56)      |
| Dexamethasone preoperative |       |           |
| yes               | 57    | (39)      |
| no                | 87    | (61)      |
| Surgical Characteristic |       |           |
| Gross total resection | 89  | (62)      |
| Partial resection  | 55    | (38)      |
| Tumor Characteristic |   |           |
| MGMT+             | 68    | (47)      |
| MGMT-             | 76    | (53)      |
| IDH-1mut          | 19    | (13)      |
| IDH-1wt           | 125   | (87)      |
| MRI Characteristic |       |           |
| Median tumor volume (T1+contrast) | 29.75 | (IQR: 36.8) |
| Median edema volume (T2) | 114  | (IQR: 120.8) |
| Edema/Tumor Ratio <3 | 72  | (50)      |
| Edema/Tumor Ratio >3 | 72  | (50)      |
| Immunologic I Characteristic (n=26) |       |           |
| Lymphocytic infiltration (median/mm²) | 0.18  | (IQR: 0.15) |
| Granulocytic infiltration (median/mm²) | 0.08  | (IQR: 0.66) |

FIGURE 2 | Representative immunohistochemistry slides with anti-CD3 (lymphocytic) and anti-CD15 (myelocytic) tumor infiltration in GBM patients allocated according to high vs low edema to tumor ratio.
months (IQR: 12) compared to 16 months OS (IQR: 19.25) and 8 months PFS (IQR: 11.75) in patients with large tumors, respectively. Preoperative volumetric tumor size was not associated with PFS (p=0.734) or OS (0.925; Figure 3A, B).

For the volumetric analysis of peritumoral edema, a median of 116.3 cm$^3$ (IQR: 120.8) was detected. Patients with peritumoral edema smaller than 116.3 cm$^3$ were defined as low edema volume and had a median OS of 16 months (IQR: 19.75) and a PFS of 8 months (IQR: 10.75) whereas patients with high edema volume had a median OS of 19 months (IQR: 19) and a median PFS of 9.5 months (IQR: 11). The volume of peritumoral edema was not associated with either PFS (p=0.55) or OS (p=0.40; Figure 3C, D).

To analyze the edema to tumor ratio, edema/tumor was calculated and a median of 3 was observed. Thus, patients with ratios under 3 were counted as having a low edema to tumor ratio and above 3 as having a high edema to tumor ratio. Patients with low edema to tumor ratio had a median OS of 15 months (IQR: 21) compared to the PFS of 8 months (IQR: 12), compared to the PFS of 9 months (IQR: 11) in patients with high preoperative edema to tumor ratio (p=0.401). In terms of OS, patients with a low preoperative edema to tumor ratio displayed a median survival of 15 months (IQR: 21) compared with 19 months (IQR: 18) in patients with a high edema to tumor ratio (p=0.551; Figures 3E, F).

**Leukocytic Tumor Infiltration in Dependence of Edema to Tumor Ratio**

In our cohort of 144 patients, immunohistochemistry was available in a total of 26 patients. In the high edema to tumor ratio group (n=9), median lymphocytic infiltration was 0.15 cells/mm$^2$ (IQR: 0.18) vs. 0.21 cells/mm$^2$ (IQR: 0.13) in the low edema to tumor ratio group (n=17) indicating that the lymphocytic tumor infiltration was not significantly correlated with edema to tumor ratio (p=0.78; 95% CI: 0.38-0.50; OR: 0.06). Furthermore, median myelocytic tumor infiltration was 0.06 cells/mm$^2$ (IQR: 0.16) in the high edema to tumor ratio group vs. 0.08 cells/mm$^2$ (IQR: 0.05) in the low edema to tumor ratio group. The myelocytic tumor infiltration was therefore not associated with edema to tumor ratio (p=0.74; 95% CI: 0.10-0.14; OR 0.02) (Table 2).

**DISCUSSION**

The major finding of our study is the significant correlation between IDH-1 status and the edema to tumor ratio. Patients harboring an IDH-1 wildtype glioblastoma presented with an increased preoperative edema to tumor ratio; however, further translational investigations are warranted to elucidate the underlaying mechanism. Furthermore, our immunohistochemistry analysis and its correlation with the edema to tumor ratio revealed that edema to tumor ratio had no significant association with lymphocytic and/or myelocytic tumor infiltration.

The interplay between cancer and immune cells is a major determinant in cancer progression and the immune system is emerging as a powerful prognostic marker and therapeutic target in neuro-oncology (10). Additionally, peritumoral edema frequently leads to neurological impairment and remains a challenging factor throughout treatment (3). Our study therefore analyzed a potential interaction between these factors.

Regarding the preoperative dexamethasone (DEX) treatment our study found no significant correlation between the extent of edema and DEX administration. Although dosage
recommendations are lacking, the routinely used synthetic corticoid DEX is clinically established for edema treatment (11, 12). However, recent studies identified several mechanisms indicating that administration of DEX in patients with GBM may not be beneficial; in fact, it may worsen the prognosis, decrease radiosensitivity, and decreased immune infiltration is certain subtypes of GBM (3, 4, 13). Considering the missing association between the extent of tumor-edema and DEX dosage in our study, this finding supports the critical review of DEX administration in GBM patients, even more so in lesions that are not strategically located (motor or sensory cortex, language cortex, insula or basal ganglia), since several recently discovered mechanisms explain the unbeneﬁcial impact of DEX on the outcome in GBM (3, 13).

Our study did not ﬁnd a signiﬁcant association between peritumoral edema or edema to tumor ratio with the extent of resection. Wu et al. recently described the negative impact of the extent of peritumoral edema (≥1 cm from tumor margin on axial MRI) on survival (6). Extensive peritumoral edema can lead to intraoperative challenges as it may obscure anatomical landmarks and complicate resection, which in turn contributes to poor survival (14, 15). Our ﬁnding does not support this proposal, since resection status was not associated with edema or edema to tumor ratio in our

FIGURE 3 | PFS and OS represented by Kaplan-Meier curves for high vs. low preoperative tumor volume (A, B), high vs. low preoperative edema volume (C, D), and high vs. low edema to tumor ratio (E, F).
One of the major findings of our analysis is the positive correlation between IDH-1 wildtype and a higher edema to tumor ratio. A few studies have investigated the association of IDH-1 status with morphological MRI analysis in low grade gliomas (16). IDH-1 mutated tumors present frequently with a unilateral pattern of growth, sharply defined tumor margins, homogeneous signal intensity, and less contrast enhancement on MRI. All these factors might contribute to the improved prognosis of patients with this subtype of GBM; however, an association between edema and IDH-1 is not described in the literature (16). The IDH-1 mutation leads to neo-enzymatic activity of the IDH-1 enzyme which drives the conversion of isocitrate into 2-hydroxyglutarate (2-HG), leading to a genomewide histone- and DNA methylation alternations (17, 18). One of these consequences is the increased hypoxia-inducible factor 1-alpha (HIF-1α) that is frequently detected in patients with an IDH-1 mutation (19, 20). On the contrary, the proliferation rate (Ki-67) and vascular endothelial growth factor (VEGF) levels are significantly lower in IDH-1 mutated tumors (21, 22). However, little is known about the affinity for vasogenic edema in IDH-1 wildtype GBM (23). Our findings encourage further translational investigations into the mechanism of peritumoral edema in GBM wildtype.

Several studies have investigated the extent of peritumoral edema and correlated it with patient’s outcome but the results were conflicting and a consistent conclusion is therefore absent (1, 6, 24). In a multicenter analysis, Schoenege et al. identified edema as an independent prognostic factor for poor outcome in GBM (1). On the contrary, Lacroix et al. published their results including more than 400 GBM patients where the extent of peritumoral edema was not found to be an independent prognostic factor (25). In our study, neither tumor size, nor edema or a high edema to tumor ratio were associated with outcome. A possible explanation could be that the peritumoral microenvironment in brain tumor patients contains an array of other non-neoplastic cells, including vascular and other glial cells, all of which could contribute to edema formation (27). Although immunotherapy in general and CAR T administration in specific carries a risk of cerebral edema as a dreadful complication, our data implies that patients with a high edema to tumor ratio should not be excluded from further immunological studies (31, 32).

We did analyze a large number of patients with extensive radiological and immunohistological parameters, whereas histopathological analysis was only available in nearly 20% of the cases. As a limitation, the investigated cohort is from 2008-2013. Although all patients in our cohort received the temozolomide based radio-chemotherapy which still is the standard of care, novel therapies such as T-Fields could not have been investigated. Our cohort is representative of GBM patients since the molecular profile is congruent with the literature (~10% IDH mutated GBM in the literature and in 13% in our cohort) (18). As further limitation and potentially introducing a bias, this investigation was a single centre study and of retrospective design.

In conclusion, the present study found no association between the extent of edema and immunogenic infiltration; however, IDH wildtype GBM was found to be more likely associated with extensive peritumoral edema than IDH mutant GBM. Further translational investigations are necessary to evaluate the underlying mechanism and the clinical relevance of this observation.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

For this retrospective analysis, an ethical approval was obtained from the ethics committee of the University Hospital Frankfurt, Germany, (Identification number: 20-676). As a non-interventional single-center study, no patient consent was necessary.

AUTHOR CONTRIBUTIONS

DD collected the data and wrote the first draft. FG supervised the manuscript. All authors contributed to critical review and revision of the manuscript. All authors contributed to the article and approved the submitted version.
REFERENCES

1. Schoenegger K, Oberndorfer S, Wuschitz B, Struhl W, Hainfellner J, Prayer D, et al. Peritumoral edema on MRI at initial diagnosis: an independent prognostic factor for glioblastoma. *Eur J Neurol* (2009) 16:874–8. doi: 10.1111/j.1468-1331.2009.02613.x

2. Stummer W. Mechanisms of tumor-related brain edema. *Neurosurge Focus* (2007) 22(5):E8. doi: 10.3171/foc.2007.22.5.9

3. Dubinski D, Hattingen E, Senft C, Seifert V, Peters KG, Reiss Y, et al. Controversial roles for dexamethasone in glioblastoma – Opportunities for novel vascular targeting therapies. *J Cereb Blood Flow Metab* (2019) 39(8):0271678X19859847. doi: 10.1177/0271678X19859847

4. Dubinski D, Won S-Y, Gessler F, Quick-Weller J, Behmanesh B, Bernatz S, et al. Dexamethasone-induced leukoencephalopathy is associated with poor survival in newly diagnosed glioblastoma. *J Neurooncol* (2018) 137:503–10. doi: 10.1007/s11060-018-2761-4

5. Yan JL, Li C, Boonzaier NR, Fountain DM, Larkin TJ, Matys T, et al. Multimodal MRI characteristics of the glioblastoma infiltration beyond contrast enhancement. *Ther Adv Neurol Disord* (2019) 12. doi: 10.1177/1756286418846641

6. Wu C-X, Lin G-S, Lin Z-X, Zhang J-D, Liu S-Y, Zhou C-F. Peritumoral edema and overall survival time in patients with brain metastases. *Edema*. *J Neuropathol Exp Neurol* (2018) 77:877. doi: 10.1093/jnen/nly064

7. Uematsu H, Maeda M, Itoh H. Peritumoral brain edema in intracranial tumors and its florid manifestation: a clinicopathological analysis of 126 cases. *Neurosurg Focus* (2011) 22(5):E8. doi: 10.3171/foc.2011.22.5.9

8. Cohen AL, Holmen SL, Colman H. IDH1 and IDH2 mutations in gliomas. *Curr Neurol Neurosci Rep* (2013) 13:1–7. doi: 10.1007/s11910-013-0345-4

9. Sulkowski PL, Corso CD, Robinson ND, Scanlon SE, Purshouse KR, Bai H, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. *Sci Transl Med* (2017) 9:eaa12463. doi: 10.1126/scitranslmed.aal2463

10. Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. *EMBO Rep* (2011) 12:463–9. doi: 10.1038/embr.2011.43

11. Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, et al. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. *Oncotarget* (2015) 6:30232–8. doi: 10.18632/oncotarget.4920

12. Polivka J, Pešta P, Pitule P, Hes O, Holubec L, Polivka J, et al. IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. *Oncotarget* (2018) 9:16462–76. doi: 10.18632/oncotarget.24536

13. Huang LE. Friend or foe-IDH1 mutations in glioma 10 years on. *Carcinogenesis* (2019) 40:1299–307. doi: 10.1038/carcin/bgr134

14. Hammond MA. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. *J Neurooncol* (1996) 27:65–73. doi: 10.1007/BF00160886

15. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. *J Neurosurg* (2001) 95:190–8. doi: 10.3171/jns.2001.95.2.190

16. Aubry M, de Tayrac M, Etcheverry A, Claveur A, Saikali S, Menel P, et al. From the core to beyond the margin: A genomic picture of glioblastoma intratumor heterogeneity. *Oncotarget* (2015) 6:12094–109. doi: 10.18632/oncotarget.3297

17. Chen Z, Hambardzumyan D. Immune microenvironment in glioblastoma subtypes. *Front Immunol* (2018) 9:10004. doi: 10.3389/fimmu.2018.01004

18. Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT02844062 (Accessed April 13, 2020).

19. Bagley SJ, Asa SL, Linette GP, June CH, O'Connor MP, et al. Pilot trial of autologous anti-EGFRvIII CAR T cells in recurrent glioblastoma multiforme. *CNS Drugs* (2016) 30:391–405. doi: 10.1007/s40263-016-0582-9

20. Berghoff AS, Fuchs E, Ricken G, Melenick B, Bindea G, Spanberger T, et al. Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. *Oncoimmunology* (2016) 5:2162–402X. doi: 10.21037/2162402X.2015.1057388

21. Gust J, Taraseviciute A, Turtle CJ. Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. *CNS Drugs* (2018) 32:1091–101. doi: 10.1007/s40263-018-0582-9

22. Torre M, Solomon IH, Sutherland CL, Nikiforow S, DeAngelo DJ, Stone RM, et al. Neutrophil polymorphonuclear infiltration and homologous recombination in glioblastoma. *Neuro Oncol* (2018) 20:1429–38. doi: 10.1093/neuonc/noy032

23. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Dubinski, Won, Rauch, Behmanesh, Ngsaan, Baumgarten, Senft, Harter, Bernstock, Freiman, Seifert and Gessler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.